{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:04:06Z","timestamp":1792019046044,"version":"4.4.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07646-1","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:23:01Z","timestamp":1766733781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances"],"prefix":"10.1186","volume":"24","author":[{"given":"Mahsa","family":"Fatahichegeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5511-4717","authenticated-orcid":false,"given":"Mohammad Amin","family":"Ansarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"1","key":"7646_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","volume":"4","author":"N M\u00f6hn","year":"2022","unstructured":"M\u00f6hn N, Bonda V, Grote-Levi L, Panagiota V, Fr\u00f6hlich T, Schultze-Florey C, Wattjes MP, Beutel G, Eder M, David S. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurol Res Pract. 2022;4(1):1.","journal-title":"Neurol Res Pract"},{"key":"7646_CR2","doi-asserted-by":"publisher","first-page":"1392831","DOI":"10.3389\/fneur.2024.1392831","volume":"15","author":"MW Han","year":"2024","unstructured":"Han MW, Jeong SY, Suh CH, Park H, Guenette JP, Huang RY, Kim KW, Yoon DH. Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis. Front Neurol. 2024;15:1392831.","journal-title":"Front Neurol"},{"issue":"5","key":"7646_CR3","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00415-023-11595-4","volume":"270","author":"U Pensato","year":"2023","unstructured":"Pensato U, Amore G, Muccioli L, Sammali S, Rondelli F, Rinaldi R, D\u2019Angelo R, Nicodemo M, Mondini S, Sambati L. CAR t-cell therapy in BOlogNa\u2013NEUrotoxicity treatment and assessment in lymphoma (CARBON\u2013NEUTRAL): proposed protocol and results from an Italian study. J Neurol. 2023;270(5):2659\u201373.","journal-title":"J Neurol"},{"issue":"6","key":"7646_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","volume":"5","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, Snyder S, McGarvey N, Gitlin M, Pelletier C. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel\u2013treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695\u2013705.","journal-title":"Blood Adv"},{"issue":"6","key":"7646_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jtct.2024.01.074","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kr\u00f6ger N. Axicabtagene Ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis. Transplantation Cell Therapy. 2024;30(6):584. e581-584. e513.","journal-title":"Transplantation Cell Therapy"},{"issue":"26","key":"7646_CR6","first-page":"3722","volume":"139","author":"J Gauthier","year":"2022","unstructured":"Gauthier J, Gazeau N, Hirayama AV, Hill JA, Wu V, Cearley A, Perkins P, Kirk A, Shadman M, Chow VA. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood J Am Soc Hematol. 2022;139(26):3722\u201331.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"7646_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","volume":"4","author":"M Pennisi","year":"2020","unstructured":"Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi C. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676\u201386.","journal-title":"Blood Adv"},{"issue":"7","key":"7646_CR8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","volume":"4","author":"RT Maziarz","year":"2020","unstructured":"Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4(7):1440\u20137.","journal-title":"Blood Adv"},{"issue":"20","key":"7646_CR9","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood J Am Soc Hematol. 2023;141(20):2430\u201342.","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"7646_CR10","doi-asserted-by":"publisher","first-page":"e005459","DOI":"10.1136\/jitc-2022-005459","volume":"10","author":"Y Amidi","year":"2022","unstructured":"Amidi Y, Eckhardt CA, Quadri SA, Malik P, Firme MS, Jones DK, Jain A, Danish HH, Rubin DB, Jacobson CA. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J Immunother Cancer. 2022;10(11):e005459.","journal-title":"J Immunother Cancer"},{"key":"7646_CR11","doi-asserted-by":"crossref","unstructured":"Cook MS, King E, Flaherty KR, Siddika K, Papa S, Benjamin R, Schurich A. CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. Cell Rep. 2025;44(7).","DOI":"10.1016\/j.celrep.2025.115973"},{"issue":"10","key":"7646_CR12","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3390\/cancers15102767","volume":"15","author":"L Wu","year":"2023","unstructured":"Wu L, Chen J, Cai R, Wang X, Liu Y, Zheng Q, Li L. Difference in efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy containing 4-1BB and CD28 co-stimulatory domains for B-cell acute lymphoblastic leukemia. Cancers. 2023;15(10):2767.","journal-title":"Cancers"},{"issue":"1","key":"7646_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12935-021-01972-2","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Chen K, Qian L, Wang P. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int. 2021;21(1):262.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"7646_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7646_CR15","doi-asserted-by":"publisher","first-page":"e005878","DOI":"10.1136\/jitc-2022-005878","volume":"11","author":"C Bove","year":"2023","unstructured":"Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, De Lucia A, Bergamini A, Bondanza A, Ciceri F. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J Immunother Cancer. 2023;11(1):e005878.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"7646_CR16","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","volume":"28","author":"AC Boroughs","year":"2020","unstructured":"Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CB, Lorrey SJ, Ashenberg O, Jerby L, Hofree M. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq. Mol Ther. 2020;28(12):2577\u201392.","journal-title":"Mol Ther"},{"key":"7646_CR17","doi-asserted-by":"crossref","unstructured":"Weinkove R, George P, Fyfe R, Hurley A, Dasyam N, Nouri Y, Ostapowicz T, Mullins S, Giunti G, Lavender B. A phase 1 dose escalation and expansion trial of third-generation CD19-directed CAR T-cells incorporating CD28 and toll-like receptor 2 (TLR2) co-stimulation for relapsed or refractory B-cell non-hodgkin lymphomas (ENABLE-1). In.: American Society of Hematology Washington, DC; 2024.","DOI":"10.1182\/blood-2023-178872"},{"issue":"1","key":"7646_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","volume":"23","author":"B He","year":"2025","unstructured":"He B, Lin R, Xu N, Qin L, Wang Z, Wang Q, Li X, Wei X, Wei Y, Tang Z. Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial. J Translational Med. 2025;23(1):594.","journal-title":"J Translational Med"},{"key":"7646_CR19","doi-asserted-by":"crossref","unstructured":"Gomez-Llobell M, Serra Smith C, G\u00f3mez-Costas D, G\u00f3mez-Centuri\u00f3n I, Garc\u00eda Dom\u00ednguez JM, Escudero-Vilaplana V, Fern\u00e1ndez Bullido Y, Carbonell D, Pion M, Bail\u00e9n R. ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling. Bone Marrow Transplant. 2025:1\u201310.","DOI":"10.1038\/s41409-025-02679-y"},{"key":"7646_CR20","doi-asserted-by":"publisher","first-page":"1110647","DOI":"10.3389\/fneur.2023.1110647","volume":"14","author":"OH Butt","year":"2023","unstructured":"Butt OH, Zhou AY, Ances BM, DiPersio JF, Ghobadi A. A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Front Neurol. 2023;14:1110647.","journal-title":"Front Neurol"},{"issue":"5","key":"7646_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","volume":"3","author":"NY Saini","year":"2022","unstructured":"Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in Axicabtagene Ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discovery. 2022;3(5):385\u201393.","journal-title":"Blood Cancer Discovery"},{"issue":"5","key":"7646_CR22","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.3390\/cimb46050288","volume":"46","author":"P Evangelidis","year":"2024","unstructured":"Evangelidis P, Evangelidis N, Kalmoukos P, Kourti M, Tragiannidis A, Gavriilaki E. Genetic susceptibility in endothelial injury syndromes after hematopoietic cell transplantation and other cellular therapies: climbing a steep hill. Curr Issues Mol Biol. 2024;46(5):4787\u2013802.","journal-title":"Curr Issues Mol Biol"},{"key":"7646_CR23","doi-asserted-by":"publisher","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol. 2024;14:1396490.","journal-title":"Front Oncol"},{"issue":"6","key":"7646_CR24","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR\u2010T treatment. WIREs Mech Disease. 2022;14(6):e1576.","journal-title":"WIREs Mech Disease"},{"key":"7646_CR25","doi-asserted-by":"publisher","first-page":"1108297","DOI":"10.3389\/fneur.2023.1108297","volume":"14","author":"V Genoud","year":"2023","unstructured":"Genoud V, Migliorini D. Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Front Neurol. 2023;14:1108297.","journal-title":"Front Neurol"},{"key":"7646_CR26","first-page":"145","volume":"141","author":"JH Rees","year":"2022","unstructured":"Rees JH. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). EBMT\/EHA CAR-T Cell Handb. 2022;141:145.","journal-title":"EBMT\/EHA CAR-T Cell Handb"},{"key":"7646_CR27","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1182\/blood-2024-198872","volume":"144","author":"E Bezerra","year":"2024","unstructured":"Bezerra E, Durisek G III, Zhao Q, Denlinger N, Voorhees T, Sanchez-Petitto G, Cottini F, Sigmund AM, Sawalha Y, Shindiapina P. Association between Post-CART terminal complement complex levels and immune effector Cell-Associated neurotoxicity syndrome (ICANS). Blood. 2024;144:3446.","journal-title":"Blood"},{"issue":"16suppl","key":"7646_CR28","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1200\/JCO.2024.42.16_suppl.7036","volume":"42","author":"Q George, Zhao","year":"2024","unstructured":"George, Zhao Q, Voorhees T, Denlinger N, Epperla N, Sigmund AM, Sanchez-Petitto G, Sawalha Y, Bond DA, Choe HK, et al. Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell\u2013associated neurotoxicity syndrome (ICANS). J Clin Oncol. 2024;42(16suppl):7036\u20137036.","journal-title":"J Clin Oncol"},{"key":"7646_CR29","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1182\/blood-2024-211204","volume":"144","author":"A Al Zaki","year":"2024","unstructured":"Al Zaki A, Sutton M, Rehman A, Le CC, Gammon S, Napoli A, Yang P, Saini NY, Ahmed S, Issa GC. Imaging activated innate immune myeloid cells in immune effector cell-associated neurotoxicity syndrome (Icans) following car T-cell therapy. Blood. 2024;144:3428.","journal-title":"Blood"},{"issue":"6","key":"7646_CR30","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","volume":"36","author":"MJ Cox","year":"2022","unstructured":"Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022;36(6):1635\u201345.","journal-title":"Leukemia"},{"issue":"13","key":"7646_CR31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood.2024023933","volume":"144","author":"C Diorio","year":"2024","unstructured":"Diorio C, Hernandez-Miyares L, Espinoza DA, Banwell BL, Bar-Or A, DiNofia AM, Barz Leahy A, Martinez Z, Myers RM, Hopkins SE. Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents. Blood. 2024;144(13):1387\u201398.","journal-title":"Blood"},{"issue":"1","key":"7646_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Experimental Clin Cancer Res. 2021;40(1):367.","journal-title":"J Experimental Clin Cancer Res"},{"key":"7646_CR33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2023-179226","volume":"142","author":"E Galli","year":"2023","unstructured":"Galli E, Modoni A, Battistini L, Rossi M, Guerrera G, Pansini I, Hohaus S, Bacigalupo A, Sica S, Chiusolo P. Blood-brain barrier and neuronal damage during Icans in patients treated with Anti-CD19 CAR-T cells. Blood. 2023;142:2128.","journal-title":"Blood"},{"key":"7646_CR34","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cell\u2013associated neurotoxicity. Front Immunol. 2020;11:577027.","journal-title":"Front Immunol"},{"issue":"6","key":"7646_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","volume":"7","author":"J Gust","year":"2023","unstructured":"Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, Wu QV, Park JR, Gardner RA, Annesley CE. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients. Blood Adv. 2023;7(6):1001\u201310.","journal-title":"Blood Adv"},{"key":"7646_CR36","doi-asserted-by":"publisher","first-page":"1378944","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek L, Jan\u017ei\u010d L, Ihan A, Kopitar AN. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. Front Immunol. 2024;15:1378944.","journal-title":"Front Immunol"},{"key":"7646_CR37","doi-asserted-by":"crossref","unstructured":"Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Sali\u00e9 H, Athanassopoulos D. Immune-effector-cell-associated-neurotoxicity-syndrome (ICANS) pathophysiology is mediated by microglia TGF-\u03b2-activated kinase-1 signaling. In.: American Society of Hematology Washington, DC; 2023.","DOI":"10.1182\/blood-2023-184867"},{"key":"7646_CR38","unstructured":"III G, Zhao Q, Voorhees T, Denlinger N, Epperla N, Sigmund AM, Sanchez-Petitto G, Sawalha Y, Bond DA, Choe HK. Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell\u2013associated neurotoxicity syndrome (ICANS). In.: American Society of Clinical Oncology. 2024."},{"issue":"4","key":"7646_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7646_CR40","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","volume":"11","author":"BD Brown","year":"2021","unstructured":"Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, Petropoulos D, Slopis JM, Sadighi Z, Khazal S. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis? Front Oncol. 2021;11:634445.","journal-title":"Front Oncol"},{"issue":"3","key":"7646_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","volume":"42","author":"C Traube","year":"2014","unstructured":"Traube C, Silver G, Kearney J, Patel A, Atkinson TM, Yoon MJ, Halpert S, Augenstein J, Sickles LE, Li C. Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU. Crit Care Med. 2014;42(3):656\u201363.","journal-title":"Crit Care Med"},{"issue":"01","key":"7646_CR42","doi-asserted-by":"publisher","first-page":"024","DOI":"10.1055\/s-0041-1728784","volume":"12","author":"N Gupta","year":"2023","unstructured":"Gupta N, Talathi S, Woolley A, Wilson S, Franklin M, Robbins J, Colston C, Hayes L. Performance of Cornell assessment of pediatric delirium scale in mechanically ventilated children. J Pediatr Intensive Care. 2023;12(01):024\u201330.","journal-title":"J Pediatr Intensive Care"},{"issue":"2S","key":"7646_CR43","first-page":"S123","volume":"110","author":"M Picard","year":"2022","unstructured":"Picard M, Sterin A, Bay J-O, Courbon C, Moreau A-S, Paul F, Pochon C, Tudesq J-J, Vicente C, Yakoub-Agha M. Management of neurotoxicity following CAR-T cell therapy: recommendations of the SFGM-TC. Bull Cancer. 2022;110(2S):S123\u201331.","journal-title":"Bull Cancer"},{"issue":"2","key":"7646_CR44","first-page":"S183","volume":"30","author":"H Shalabi","year":"2024","unstructured":"Shalabi H, McGuire J, Pinto S, Bhatia A, Oztek MA, Shah R, Vossough A, Wright J, Carapia NT, Harrison C. Neuroimaging findings during immune effector cell associated neurotoxicity syndrome (ICANS)-a CAR T cell neurotoxicity imaging virtual archive (CARNIVAL) study. Transplantation Cell Therapy Official Publication Am Soc Transplantation Cell Therapy. 2024;30(2):S183\u20134.","journal-title":"Transplantation Cell Therapy Official Publication Am Soc Transplantation Cell Therapy"},{"issue":"1","key":"7646_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/ijms25010644","volume":"25","author":"SN Pinto","year":"2024","unstructured":"Pinto SN, Krenciute G. The mechanisms of altered blood\u2013brain barrier permeability in CD19 CAR T\u2013cell recipients. Int J Mol Sci. 2024;25(1):644.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"7646_CR46","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/10428194.2022.2074990","volume":"63","author":"AH Lapidus","year":"2022","unstructured":"Lapidus AH, Anderson MA, Harrison SJ, Dickinson M, Kalincik T, Lasocki A. Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Leuk Lymphoma. 2022;63(10):2364\u201374.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"7646_CR47","doi-asserted-by":"publisher","first-page":"20011","DOI":"10.1038\/s41598-022-24010-1","volume":"12","author":"DK Jones","year":"2022","unstructured":"Jones DK, Eckhardt CA, Sun H, Tesh RA, Malik P, Quadri S, Firme MS, van Sleuwen M, Jain A, Fan Z. EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Sci Rep. 2022;12(1):20011.","journal-title":"Sci Rep"},{"issue":"4","key":"7646_CR48","first-page":"e200111","volume":"10","author":"S Huby","year":"2023","unstructured":"Huby S, Gelisse P, Tudesq J-J, Labauge P, Duflos C, Cartron G, Gallerand M-A, Platon L, Badiou S, Lamure S. Frontal intermittent rhythmic delta activity is a useful diagnostic tool of neurotoxicity after CAR T-cell infusion. Neurology: Neuroimmunol Neuroinflammation. 2023;10(4):e200111.","journal-title":"Neurology: Neuroimmunol Neuroinflammation"},{"key":"7646_CR49","doi-asserted-by":"publisher","first-page":"1070379","DOI":"10.3389\/fimmu.2022.1070379","volume":"13","author":"V Bonetto","year":"2022","unstructured":"Bonetto V, Pasetto L, Lisi I, Carbonara M, Zangari R, Ferrari E, Punzi V, Luotti S, Bottino N, Biagianti B. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front Immunol. 2022;13:1070379.","journal-title":"Front Immunol"},{"key":"7646_CR50","doi-asserted-by":"crossref","unstructured":"Storci G, De Felice F, Ricci F, Santi S, Messelodi D, Bertuccio SN, Laprovitera N, Dicataldo M, Rossini L, De Matteis S. CAR\u2009+\u2009extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells. J Clin Invest. 2024;134(14).","DOI":"10.1172\/JCI173096"},{"issue":"7","key":"7646_CR51","first-page":"697","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M. GM-CSF Inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood J Am Soc Hematol. 2019;133(7):697\u2013709.","journal-title":"Blood J Am Soc Hematol"},{"issue":"35","key":"7646_CR52","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7646_CR53","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/biom13020382","volume":"13","author":"T Lakomy","year":"2023","unstructured":"Lakomy T, Akhoundova D, Nilius H, Kronig M-N, Novak U, Daskalakis M, Bacher U, Pabst T. Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome. Biomolecules. 2023;13(2):382.","journal-title":"Biomolecules"},{"issue":"1","key":"7646_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/19418744221128852","volume":"13","author":"S Satyanarayan","year":"2023","unstructured":"Satyanarayan S, Spiegel J, Hovsepian D, Markert M, Thomas R, Muffly L, Miklos D, Graber K, Scott BJ. Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. Neurohospitalist. 2023;13(1):53\u201360.","journal-title":"Neurohospitalist"},{"issue":"1","key":"7646_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s44231-023-00054-3","volume":"4","author":"MN Bulloch","year":"2024","unstructured":"Bulloch MN, Cardinale-King M, Cogle S, Radparvar S, Effendi M, Jagpal S, Dixit D. Correction of electrolyte abnormalities in critically ill patients. Intensive Care Res. 2024;4(1):19\u201337.","journal-title":"Intensive Care Res"},{"issue":"1","key":"7646_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40635-021-00370-2","volume":"9","author":"T Materski","year":"2021","unstructured":"Materski T, John M, Pirani T, Benjamin R, Kuhnl A, Potter V, Sanderson R, Metaxa V. Correction to: ICU-outcomes in CAR-T patients\u2014A single centre experience. Intensive Care Med Experimental. 2021;9(1):9.","journal-title":"Intensive Care Med Experimental"},{"key":"7646_CR57","doi-asserted-by":"publisher","first-page":"154511","DOI":"10.1016\/j.jcrc.2023.154511","volume":"80","author":"L Scourfield","year":"2024","unstructured":"Scourfield L, Pirani T, Singh N, Saha R, Kuhnl A, Sanderson R, Metaxa V. An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience. J Crit Care. 2024;80:154511.","journal-title":"J Crit Care"},{"issue":"12","key":"7646_CR58","doi-asserted-by":"publisher","first-page":"e0278950","DOI":"10.1371\/journal.pone.0278950","volume":"17","author":"S Chacim","year":"2022","unstructured":"Chacim S, Monjardino T, Cunha JL, Medeiros P, Redondo P, Bento MJ, Mariz JM. Costs, effectiveness, and safety associated with chimeric antigen receptor (CAR) T-cell therapy: results from a comprehensive cancer center. PLoS ONE. 2022;17(12):e0278950.","journal-title":"PLoS ONE"},{"issue":"4","key":"7646_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.medine.2022.02.005","volume":"46","author":"JS Montero","year":"2022","unstructured":"Montero JS, Gonzalez AC, Aguilar LM, Cort\u00e9s JM. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. Med Intensiva (English Edition). 2022;46(4):201\u201312.","journal-title":"Med Intensiva (English Edition)"},{"issue":"7","key":"7646_CR60","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales M-A. CD19 CAR T-cell therapy and prophylactic Anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29(7):1710\u20137.","journal-title":"Nat Med"},{"issue":"7","key":"7646_CR61","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Liang EC, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, L\u00f3pez-Corral L, Hernani R, Ortiz-Maldonado V. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplantation Cell Therapy. 2023;29(7):430\u20137.","journal-title":"Transplantation Cell Therapy"},{"issue":"5","key":"7646_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood.2023022670","volume":"143","author":"EP Darnell","year":"2024","unstructured":"Darnell EP, Frigault MJ. Two years later: CD19 CAR-T going the distance. Blood. 2024;143(5):379\u201380.","journal-title":"Blood"},{"issue":"4","key":"7646_CR63","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2020","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC. Immune reconstitution and associated infections following Axicabtagene Ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2020;106(4):978.","journal-title":"Haematologica"},{"key":"7646_CR64","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.1182\/blood-2024-203356","volume":"144","author":"P Lafeuille","year":"2024","unstructured":"Lafeuille P, Shafquat A, Sang C, Beigi M, Maura F, Aptekar J. Using synthetic data produced by artificial intelligence (AI) to generate insights for chimeric antigen receptor T-cell (CAR T-cell) clinical trials. Blood. 2024;144:7484.","journal-title":"Blood"},{"issue":"2","key":"7646_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318.","journal-title":"Curr Hematol Malig Rep"},{"key":"7646_CR66","doi-asserted-by":"crossref","unstructured":"Sterner RM, Cox MJ, Sakemura R, Kenderian SS. Using CRISPR\/Cas9 to knock out GM-CSF in CAR-T cells. J Vis Exp. 2019(149):e59629.","DOI":"10.3791\/59629"},{"issue":"5","key":"7646_CR67","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1172\/JCI136094","volume":"130","author":"E Gavriilaki","year":"2020","unstructured":"Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Investig. 2020;130(5):2152\u201363.","journal-title":"J Clin Investig"},{"issue":"9","key":"7646_CR68","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41434-023-00404-2","volume":"30","author":"L Bouquet","year":"2023","unstructured":"Bouquet L, B\u00f4le-Richard E, Warda W, Neto Da Rocha M, Trad R, Nicod C, Haderbache R, Genin D, Ferrand C, Deschamps M. RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells. Gene Ther. 2023;30(9):706\u201313.","journal-title":"Gene Ther"},{"issue":"3","key":"7646_CR69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","volume":"21","author":"C Roddie","year":"2019","unstructured":"Roddie C, O\u2019Reilly M, Pinto JDA, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21(3):327\u201340.","journal-title":"Cytotherapy"},{"issue":"1","key":"7646_CR70","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12967-023-04041-6","volume":"21","author":"P Celichowski","year":"2023","unstructured":"Celichowski P, Turi M, Charv\u00e1tov\u00e1 S, Radhakrishnan D, Feizi N, Chyra Z, \u0160im\u00ed\u010dek M, Jel\u00ednek T, Bago JR, H\u00e1jek R. Tuning cars: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. J Translational Med. 2023;21(1):197.","journal-title":"J Translational Med"},{"issue":"4","key":"7646_CR71","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40259-023-00610-9","volume":"37","author":"LC Testa","year":"2023","unstructured":"Testa LC, Musunuru K. Base editing and prime editing: potential therapeutic options for rare and common diseases: LC testa. BioDrugs. 2023;37(4):453\u201362.","journal-title":"BioDrugs"},{"issue":"Supplement 1","key":"7646_CR72","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1182\/blood-2023-181869","volume":"142","author":"EJ Pomeroy","year":"2023","unstructured":"Pomeroy EJ, Anzalone AV, Podracky CJ, Bloch NB, Chang R, Dwivedi AA, Laoharawee K, Wilhelm AJ, Waterman DP, Tedeschi JG, et al. Multiplex prime editing and PASSIGE TM for Non-Viral generation of an allogeneic CAR-T cell product. Blood. 2023;142(Supplement 1):4803\u20134803.","journal-title":"Blood"},{"key":"7646_CR73","doi-asserted-by":"publisher","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco R, Mussetti A, Villagr\u00e1n-Garc\u00eda M, Sureda A. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern? Front Neurol. 2023;14:1144414.","journal-title":"Front Neurol"},{"issue":"14","key":"7646_CR74","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"7646_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jtct.2025.01.884","volume":"31","author":"L Maillie","year":"2025","unstructured":"Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C. Prolonged neurologic symptoms following immune effector cell-Associated neurotoxicity syndrome in patients with large B-cell lymphoma treated with chimeric antigen Receptor-Modified T cell therapy. Transplantation Cell Therapy. 2025;31(4):228\u201335.","journal-title":"Transplantation Cell Therapy"},{"issue":"4","key":"7646_CR76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000530743","volume":"146","author":"M Nishimoto","year":"2023","unstructured":"Nishimoto M, Takakuwa T, Kuno M, Makuuchi Y, Okamura H, Nakashima Y, Koh H, Namba H, Itoh Y, Hino M. Recapitulated late-onset inflammatory toxicities and progressive Dysautonomia with persistence of central memory CD4\u2009+\u2009chimeric antigen receptor T cells in a case of transformed follicular lymphoma: case report. Acta Haematol. 2023;146(4):341\u20135.","journal-title":"Acta Haematol"},{"issue":"16suppl","key":"7646_CR77","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1200\/JCO.2024.42.16_suppl.7034","volume":"42","author":"JJ Huang","year":"2024","unstructured":"Huang JJ, Liang EC, Albittar A, Portuguese AJ, Wuliji N, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Shadman M, et al. Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees. J Clin Oncol. 2024;42(16suppl):7034\u20137034.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7646_CR78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13550-024-01172-9","volume":"14","author":"B Ferrer-Lores","year":"2024","unstructured":"Ferrer-Lores B, Ortiz-Algarra A, Pic\u00f3-Peris A, Estepa-Fern\u00e1ndez A, Bellv\u00eds-Bataller F, Weiss GJ, Fuster-Matanzo A, Fern\u00e1ndez JP, Jimenez-Pastor A, Hernani R. Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model. EJNMMI Res. 2024;14(1):113.","journal-title":"EJNMMI Res"},{"key":"7646_CR79","doi-asserted-by":"publisher","first-page":"251513552413058","DOI":"10.1177\/25151355241305856","volume":"12","author":"M Shahzadi","year":"2024","unstructured":"Shahzadi M, Rafique H, Waheed A, Naz H, Waheed A, Zokirova FR, Khan H. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives. Therapeutic Adv Vaccines Immunotherapy. 2024;12:25151355241305856.","journal-title":"Therapeutic Adv Vaccines Immunotherapy"},{"issue":"6","key":"7646_CR80","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40259-022-00557-3","volume":"36","author":"B Ghanem","year":"2022","unstructured":"Ghanem B, L <>Shi. The economic burden of CAR T cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma in the US. BioDrugs. 2022;36(6):773\u201380.","journal-title":"BioDrugs"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07646-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:05:14Z","timestamp":1769605514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7646"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07646-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}